Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like These Are the 4 Most Admired Life Science Companies in the World February 21, 2017 Flushed With Cash, Shanghai Pharma Hunts for M&A in the U.S. and Europe January 23, 2018 Why This Pharma May be the Best CAR-T Bet, Not Gilead October 19, 2017
